Glidiab MV
Glydiab MR is an oral medication containing Gliclazide, primarily used for managing type 2 diabetes mellitus. It belongs to the sulfonylurea class of drugs, which help increase insulin production from the pancreas, leading to better blood glucose control. Glydiab MR is formulated as modified-release tablets, ensuring a gradual release of the active ingredient for prolonged effect. These tablets are typically taken once daily, providing convenience for patients managing complex diabetes regimens. Suitable for adults, Glydiab MR is often used in conjunction with dietary measures and physical activity to enhance its efficacy. Regular monitoring of blood sugar levels is recommended to ensure optimal therapeutic outcomes. Always adhere to prescribed dosages for maximum benefit.Active substance:
GliclazidePharmachologic effect:
Gliclazide is a sulfonylurea antidiabetic medication that stimulates insulin secretion from the beta cells of the pancreas. It helps to lower blood glucose levels by increasing the release of insulin.Indications:
- Type 2 diabetes mellitus when diet, exercise, and weight reduction alone are not adequate.
Contraindications:
- Hypersensitivity to gliclazide or any of the excipients
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Diabetic pre-coma and coma
- Severe renal or hepatic insufficiency
- Treatment with miconazole
- Pregnancy and lactation
Side effects:
In order of decreasing probability: Hypoglycemia, Nausea, Abdominal pain, Diarrhea, Constipation, Rash, Pruritus, Erythema, Dizziness, Headache
Dosing and Administration:
The recommended starting dose is 30 mg once daily. The dose may be adjusted in increments of 30 mg, based on the patient's response, up to a maximum of 120 mg per day. The tablet should be taken with breakfast.
Storage:
Store at a temperature not exceeding 25°C (77°F).
Glidiab MV
in Cyrillic : Глидиаб МВ
SUBSTANCE
Gliclazide
DOSAGE FORM
tablets
